BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Company Overview

Boehringer Ingelheim International GmbH is a research-driven group of companies whose main businesses are human pharmaceuticals and animal health. The human pharma focuses on fields such as cardiovascular-renal-metabolic diseases, oncology, respiratory issues, immunology, mental health, and retinal health. The animal health segment provides vaccines and treatments for companion animals and livestock and supports efforts to combat transboundary diseases.

Boehringer Ingelheim caters to diabetes through its human pharma division. Its flagship product, Jardiance, is essential in managing type 2 diabetes while treating chronic heart failure and kidney disease. It operates in more than 130 markets worldwide. It maintains R&D and production networks, with hubs in Germany, the U.S., Austria, Japan, France, and China, as well as manufacturing facilities across the U.S., Europe, and Asia.

Financial Highlights (FY 2025)

Company's Business Segments

• Human Pharma : This segment focuses on cardiovascular and metabolic diseases, respiratory diseases, oncology, mental health, immunology, and retinal diseases.
• Animal Health : The segment portfolio includes products for pets, horses, swine, ruminants, and poultry.